Strong Balance Sheet / Low LeverageA low debt-to-equity ratio and strong equity base provide durable financial flexibility, reducing refinancing and solvency risk. This supports funding of working capital, opportunistic capex or R&D and shields operations from cyclical shocks over the next several months.

Stable Margins With Recent EBIT/EBITDA ImprovementConsistently stable gross and net margins and recent EBIT/EBITDA improvement indicate operational control and pricing power. Margin resilience can sustain earnings quality and cash generation even if revenue lags, supporting longer-term profitability and strategic investments.

Positive Return On EquityA positive ROE signals the company generates returns from shareholders' capital, reflecting underlying business profitability. Coupled with a high equity ratio, this supports reinvestment capacity and provides a cushion for funding growth or absorbing near-term shocks.

Bears Say

Significant Recent Revenue DeclineA nearly 29% revenue decline is a material structural weakness, reducing scale benefits and limiting room to absorb fixed costs. Persisting revenue contraction would undermine cash generation, investment capacity and margin sustainability over the coming months.

Negative Free Cash Flow And Weak Cash ConversionRecent negative free cash flow and a low operating cash flow to net income ratio indicate difficulty converting accounting profits into cash. This constrains capex, working capital and increases reliance on financing, posing a durable constraint on strategic flexibility.

Volatile And Inconsistent Income PerformanceInconsistent revenue and earnings create forecasting and execution risk, making long-term planning harder. Volatility can raise funding costs, limit strategic investments and reduce stakeholder confidence if trends don't stabilize within several quarters.

Arvee Laboratories (India) Ltd. News

Arvee Laboratories to Shut Trading Window Ahead of December Quarter Results

Arvee Laboratories (India) Ltd. ( ($IN:ARVEE) ) has shared an announcement. Arvee Laboratories (India) Ltd has announced the...

2M ago

ARVEE

Arvee Laboratories Denies Any Undisclosed Events Behind Share Price Volatility

The latest update is out from Arvee Laboratories (India) Ltd. ( ($IN:ARVEE) ). Arvee Laboratories (India) Ltd. has...

3M ago

ARVEE

ARVEE FAQ

What was Arvee Laboratories (India) Ltd.’s price range in the past 12 months?

Arvee Laboratories (India) Ltd. lowest stock price was ₹134.65 and its highest was ₹290.78 in the past 12 months.

What is Arvee Laboratories (India) Ltd.’s market cap?

Arvee Laboratories (India) Ltd.’s market cap is ₹1.63B.

When is Arvee Laboratories (India) Ltd.’s upcoming earnings report date?

Arvee Laboratories (India) Ltd.’s upcoming earnings report date is May 22, 2026 which is in 69 days.

How were Arvee Laboratories (India) Ltd.’s earnings last quarter?

Arvee Laboratories (India) Ltd. released its earnings results on Feb 13, 2026. The company reported ₹1.658 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.658.

Is Arvee Laboratories (India) Ltd. overvalued?

According to Wall Street analysts Arvee Laboratories (India) Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arvee Laboratories (India) Ltd. pay dividends?

Arvee Laboratories (India) Ltd. does not currently pay dividends.

What is Arvee Laboratories (India) Ltd.’s EPS estimate?

Arvee Laboratories (India) Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arvee Laboratories (India) Ltd. have?

Arvee Laboratories (India) Ltd. has 11,020,000 shares outstanding.

What happened to Arvee Laboratories (India) Ltd.’s price movement after its last earnings report?

Arvee Laboratories (India) Ltd. reported an EPS of ₹1.658 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.977%.

Which hedge fund is a major shareholder of Arvee Laboratories (India) Ltd.?

Currently, no hedge funds are holding shares in IN:ARVEE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Arvee Laboratories (India) Ltd.

Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India. The company provides polymer modifiers, including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate; and contrast media intermediates, such as 5-nitroisophthalic acid, dimethyl 5-nitroisophthalate, monomethyl 5-nitroisophthalate, 5-hydroxyisophthalic acid, 5-aminoisophthalic acid, and dimethyl 5-aminoisophthalate, as well as 3,5-dinitrobenzoic acid and 3,5-diamino benzoic acid. It also offers drug intermediates comprising 2-acetyl thiophene, thiophene-2-carboxaldehyde, 4amino pyridine, and 2chloro5nitrobenzoic acid. In addition, the company exports its products. Arvee Laboratories (India) Ltd. was incorporated in 2012 and is based in Ahmedabad, India.